Appendix 6—table 1. Results from models for severe dengue endpoint.
| Single models | Global model | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | Children OR (95% CI) |
Adults OR (95% CI) |
Poverall | Pinteraction | ||
| VCAM-1 (ng/ml) | 1.28 (0.77–2.12) | 2.13 (0.88–5.15) | 0.236 | 0.202 | 1.20 (0.35–4.12) | 3.13 (0.19–50.77) | 0.723 | 0.491 | |
| SDC-1 (pg/ml) | 1.55 (0.41–5.96) | 3.26 (0.69–15.52) | 0.307 | 0.438 | 1.16 (0.12–11.07) | 0.87 (0.03–27.93) | 0.987 | 0.884 | |
| Ang-2 (pg/ml) | 1.42 (0.70–2.88) | 1.79 (0.97–3.31) | 0.148 | 0.580 | 1.20 (0.33–4.31) | 1.02 (0.33–3.19) | 0.961 | 0.830 | |
| IL-8 (pg/ml) | 1.04 (0.47–2.33) | 2.15 (0.67–6.88) | 0.420 | 0.338 | 0.81 (0.28–2.31) | 2.51 (0.16–38.43) | 0.741 | 0.446 | |
| IP-10 (pg/ml) | 1.32 (0.75–2.33) | 1.64 (0.58–4.62) | 0.443 | 0.708 | 0.76 (0.17–3.30) | 0.22 (0.01–7.12) | 0.693 | 0.473 | |
| IL-1RA (pg/ml) | 1.84 (0.81–4.16) | 1.78 (0.80–3.94) | 0.098 | 0.956 | 2.22 (0.51–9.64) | 3.35 (0.45–24.87) | 0.386 | 0.696 | |
| sCD163 (ng/ml) | 1.43 (0.52–3.94) | 2.43 (0.27–21.70) | 0.617 | 0.645 | 0.98 (0.27–3.59) | 2.06 (0.15–27.47) | 0.855 | 0.590 | |
| sTREM-1 (pg/ml) | 1.20 (0.44–3.28) | 1.29 (0.55–3.05) | 0.793 | 0.914 | 0.93 (0.30–2.88) | 0.38 (0.02–8.76) | 0.827 | 0.541 | |
| Ferritin (ng/ml) | 1.13 (0.59–2.16) | 1.58 (0.59–4.23) | 0.659 | 0.501 | 1.12 (0.55–2.29) | 1.34 (0.25–7.02) | 0.926 | 0.819 | |
| CRP (mg/l) | 1.16 (0.71–1.88) | 1.77 (0.56–5.62) | 0.620 | 0.418 | 0.97 (0.58–1.63) | 1.55 (0.33–7.32) | 0.773 | 0.500 |
Odds ratios (95% confidence intervals) are calculated for each 2-fold increase of the biomarkers and are estimated at age of 10 and 25 years, represented as children and adults respectively; Poverall is derived from Wald test for the overall association of the biomarker with the endpoint; Pinteraction is from the test for the interaction between the biomarker and age.